Dr. Royal is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
887 Congress St
Portland, ME 04102Phone+1 207-774-6368Fax+1 207-774-9388
Education & Training
- University of Texas M D Anderson Cancer CenterFellowship, Complex General Surgical Oncology, 2001 - 2003
- University of MarylandResidency, Surgery, 1997 - 2000
- University of RochesterFellowship, Surgery, 1994 - 1997
- National Institutes of Health Clinical CenterFellowship, Allergy and Immunology, 1993 - 1994
- Cincinnati Children's Hospital Medical CenterFellowship, Research - Pediatric Surgery, 1991 - 1993
- Wellspan Health/York HospitalResidency, Surgery, 1988 - 1991
- Oregon Health and Science University School of MedicineClass of 1988
Certifications & Licensure
- ME State Medical License 2019 - 2026
- OR State Medical License 2019 - 2025
- TX State Medical License 2001 - 2021
- OH State Medical License 1991 - 2002
- PA State Medical License 1990 - 1992
- American Board of Surgery Surgery
Awards, Honors, & Recognition
- Fellow (FACS) American College of Surgeons
Clinical Trials
- Positron Emission Tomography and CT Scan in Predicting Response in Patients With Metastatic Melanoma or Kidney Cancer Who Are Undergoing Cellular Adoptive Immunotherapy on a Surgery Branch Clinical Trial Start of enrollment: 2006 Apr 01
- Positron Emission Tomography Using [18F]-Labeled Substance P Antagonist Receptor Quantifier in Finding Disease in Patients With Pancreatic Cancer Start of enrollment: 2007 Sep 01
- Tumor and Vaccine Site With a Toll Like Receptor (TLR) Agonist Start of enrollment: 2010 May 20
- Join now to see all
Publications & Presentations
PubMed
- 98 citationsTreatment factors associated with long-term survival after cytoreductive surgery and regional chemotherapy for patients with malignant peritoneal mesotheliomaH. Richard Alexander, David L. Bartlett, James F. Pingpank, Steven K. Libutti, Richard E. Royal
Surgery. 2013-06-01 - 515 citationsPrognostic Factors Related to Clinical Response in Patients with Metastatic Melanoma Treated by CTL-Associated Antigen-4 BlockadeStephanie G. Downey, Jacob A. Klapper, Franz O. Smith, James Chih-Hsin Yang, Richard M. Sherry
Clinical Cancer Research. 2007-11-15 - 1011 citationsAdoptive Cell Therapy for Patients With Metastatic Melanoma: Evaluation of Intensive Myeloablative Chemoradiation Preparative RegimensMark E. Dudley, James Chih-Hsin Yang, Richard M. Sherry, Michael S. Hughes, Richard E. Royal
Journal of Clinical Oncology. 2008-11-10
Journal Articles
- Author Correction: Neoadjuvant Immune Checkpoint Blockade in High-Risk Resectable MelanomaJanice N Cormier, Ehab Hanna, Padmanee Sharma, Jennifer A Wargo, Isabella C Glitza, Sapna P Patel, Adi Diab, Jeffrey E Lee, Richard Royal, Randal Weber, Patrick Hwu, J..., Nature
- Publisher Correction: Neoadjuvant Immune Checkpoint Blockade in High-Risk Resectable MelanomaScott Woodman, Alexander J Lazar, Michael A Davies, Neil Gross, Sapna P Patel, Isabella C Glitza, Ehab Hanna, Stephen Y Lai, Richard Ehlers, Amy Hessel, Padmanee Sharm..., Nature
- Neoadjuvant Immune Checkpoint Blockade in High-Risk Resectable MelanomaRichard Royal, Alexander J Lazar, Adi Diab, Sapna P Patel, Jeffrey E Lee, Padmanee Sharma, Patrick Hwu, Randal Weber, Jeffrey Gershenwald, Carol Lewis, Richard Ehlers,..., Nature
Press Mentions
- Staying Positive in the Face of UncertaintyNovember 30th, 2018
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: